Aastrom Biosciences CEO to Present at Cowen & Co. 26th Annual Health Care Conference
03 March 2006 - 8:00AM
PR Newswire (US)
ANN ARBOR, Mich., March 2 /PRNewswire-FirstCall/ -- Aastrom
Biosciences, Inc. (NASDAQ:ASTM) announced today R. Douglas
Armstrong, Ph.D., Chairman and Chief Executive Officer, will
present at the Cowen & Co. 26th Annual Health Care Conference.
The conference will be held March 6-9, 2006 at the Boston Marriott
Copley Place in Boston, MA. Dr. Armstrong is scheduled to present
at 11:20am (EST) on Tuesday, March 7th. (Logo:
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO ) A live
webcast of Aastrom's presentation can be accessed by logging onto
the web at
http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ASTM&item_id=1216300.
An archived replay of the presentation will also be available after
the conference for 90 days, at the same site. About Aastrom
Biosciences, Inc. Aastrom Biosciences, Inc. (NASDAQ:ASTM) is
developing products for the repair or regeneration of multiple
human tissues, based on its proprietary Tissue Repair Cell (TRC)
adult stem cell technology. Aastrom's TRC products contain large
numbers of bone marrow stem and progenitor cells that are produced
from a small amount of cells originating from the patient. The
AastromReplicell(R) System, an industry-unique automated cell
product manufacturing platform, was developed for the production of
standardized, patient-specific TRC products. TRC products have been
used safely in humans as a substitute for bone marrow stem cells,
and are currently in clinical trials for bone grafting (long bone
fractures and spine fusion) and blood vessel regeneration (diabetic
limb ischemia) applications. The Company has recently reported
positive interim clinical trial results for its TRCs demonstrating
both the clinical safety and ability of TRCs to induce healthy new
tissue growth (long bone fractures and jaw bone reconstruction).
For more information, visit Aastrom's website at
http://www.aastrom.com/. This document contains forward-looking
statements, including without limitation, statements concerning
planned clinical trials, product development objectives, potential
advantages of TRCs, and potential product applications, which
involve certain risks and uncertainties. The forward-looking
statements are also identified through use of the words "planned,"
and other words of similar meaning. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are potential patient accrual difficulties, clinical
trial results, potential product development difficulties, the
effects of competitive therapies, regulatory approval requirements,
the availability of financial and other resources and the
allocation of resources among different potential uses. These and
other significant factors are discussed in greater detail in
Aastrom's Annual Report on Form 10-K and other filings with the
Securities and Exchange Commission. CONTACTS: Kris M. Maly Cameron
Associates Investor Relations Department Kevin McGrath Aastrom
Biosciences, Inc. Phone: (212) 245-4577 Phone: (734) 930-5777
Alyson Nikulicz - Media Phone: (212) 554-5464
http://www.newscom.com/cgi-bin/prnh/20060302/NETH028LOGO
http://photoarchive.ap.org/ DATASOURCE: Aastrom Biosciences, Inc.
CONTACT: Kris M. Maly, of Investor Relations Department at Aastrom
Biosciences, Inc., +1-734-930-5777; or Kevin McGrath,
+1-212-245-4577, or Alyson Nikulicz, +1-212-554-5464, both of
Cameron Associates for Aastrom Biosciences, Inc. Web site:
http://www.aastrom.com/
Copyright
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2023 to Jul 2024